Document is current
Any future updates will be listed below
-
Authors
Amado, Carlos A. https://orcid.org/0000-0002-5598-1753
Ghadban, Cristina
Manrique, Adriana
Osorio, Joy Selene
Ruiz de Infante, Milagros
Perea, Rodrigo
Gónzalez-Ramos, Laura
García-Martín, Sergio
Huidobro, Lucia
Zuazaga, Javier
Druet, Patricia
Argos, Pedro
Poo, Claudia
Muruzábal, Ma Josefa
España, Helena
Andretta, Guido
-
Funding
Funding for this research was provided by:
SOCALPAR (2023-1)
Universidad de Cantabria
- License Information
-
More Information
Article History
Received: 13 December 2023
Accepted: 29 April 2024
First Online: 9 May 2024
Declarations
:
: Carlos Amado has received speaker or consulting fees from Boehringer Ingelheim, Pfizer, AstraZeneca, Novartis, Chiesi, Faes Farma, Esteve and GSK. Guido Andretta has received speaker fees from AstraZeneca. Javier Zuazaga has received speaker fees from Boehringer Ingelheim. The rest of the authors do not have any conflict of interest.
: This study complies with internationally accepted standards for research practice and reporting. The ethics committee of our Institution approved the study (2023.061).
: Not applicable.
